Core Viewpoint - The company plans to adjust and postpone certain sub-projects within its fundraising investment project for drug research and development, while maintaining the total investment amount for the "Drug Research and Development Project" unchanged [1][2][3] Fundraising Investment Project Overview - The company raised a total of RMB 724.27 million by issuing 23.5 million shares at RMB 30.82 per share, with a net amount of RMB 655.65 million after deducting related expenses [1][2] - As of May 31, 2025, the cumulative investment from the raised funds amounted to RMB 408.36 million [2] Adjustments and Postponements - The adjustments involve reallocating unspent funds from completed projects to ongoing or new projects, optimizing the priority of funding based on market conditions and research progress [4][5] - The company aims to enhance the efficiency of fund usage while ensuring that the total investment in the "Drug Research and Development Project" remains unchanged [3][4] Specific Adjustments - Funds from completed projects such as "Compound Polyethylene Glycol Electrolyte Powder" and others will be redirected to ongoing projects like "Qianqing Granules" and new investment projects [5][6] - The company will extend the research timelines for projects like "Qianqing Granules" and "L-Carnitine Oral Solution" to the end of 2028, adjusting funding allocations accordingly [6][8] Research and Development Focus - The company continues to focus on projects in the digestive, respiratory, and anti-infection fields, while also expanding into pain relief, cardiovascular, neurological, and lymphatic treatment areas [8][9] - A total of RMB 47.6 million is allocated for respiratory products, and RMB 47.8 million for pain relief products, among other therapeutic areas [9][10][12] Feasibility Analysis - The company's drug research capabilities and a strong core research team support the ongoing implementation of projects, ensuring a robust pipeline for future product development [15][16] - The adjustments are made to align with market demands and the company's strategic planning, without negatively impacting normal operations or shareholder interests [17][18]

Group 1 - The company held its fourth supervisory board meeting on June 5, 2025, with all three supervisors present, complying with legal and regulatory requirements [1][2] - The supervisory board approved the proposal to terminate the data science center project and permanently allocate the remaining raised funds to supplement working capital, with a unanimous vote of 3 in favor [1][2] - The decision to terminate the project was made based on the company's actual situation and long-term development plan, aiming to improve the efficiency of fund utilization and align with the interests of the company and its shareholders [2]

江西国科军工集团股份有限公司（以下简称"公司"）于2025年3月24日召 开第三届董事会第十五次会议、第三届监事会第十五次会议，审议通过了《关于 调整部分募投项目内部投资结构的议案》，同意公司在募投项目总额不变的前提 下，对首次公开发行募集资金投资项目"统筹规划建设项目"内部投资结构进行 调整，公司监事会发表了明确的同意意见，保荐机构国泰君安证券股份有限公司 （以下简称"保荐机构"）对公司出具了明确的核查意见。 一、募集资金基本情况 国科军工: 关于调整部分募投项目内部投资结构的 公告 证券代码：688543 证券简称：国科军工 公告编号：2025-019 江西国科军工集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 经中国证券监督管理委员会证监许可［2023］1011 号文《关于同意江西国科 军工集团股份有限公司首次公开发行股票注册的批复》的核准，公司采用向社会 公开发行人民币普通股（A 股）3667 万股，发行价格为每股 43.67 元。截止 2023 年 6 月 16 日，本公司实际已向社会公开发行人 ...